Topic: bispecific antibodies
Amid the merger of Celgene and his former company Bristol-Myers Squibb, there was no room at the inn for oncologist Thomas Lynch, M.D., as CSO.
Pandion and Astellas inked a deal to discover, develop and market bispecific drugs for Type 1 diabetes and other autoimmune diseases of the pancreas.
The bispecific outperformed J&J’s blockbuster against an endpoint that tracked the proportion of patients achieving a 90% reduction in psoriasis,
The asset moved into a phase 1 advanced solid tumor trial late last year but was culled from the pipeline before delivering final data.
IGM Biotherapeutics picked up $102 million in series C financing to work on its pipeline of cancer drugs.
Paul Foster's retirement comes as Xencor moves two more programs into the clinic and works to resume a phase 1 study of its Novartis-partnered drug.
One of Bristol-Myers Squib's key executives has now jumped ship to a small British biotech.
EpimAb Therapeutics reeled in a $74 million series B to build out its bispecifics pipeline and push its lead program into phase 2 in 2020.
Adimab is continuing a dealmaking streak with three more deal expansions, with Novartis, Regeneron and Takeda.
The action sees Daiichi pay Zymeworks $3.5 million to license an asset based on its bispecific antibody platform.